A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
Clinical trial NCT03580356 · COMPLETED
Trial details
- NCT number
- NCT03580356
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-20
- Primary completion
- 2021-06-22
- Enrollment
- 1078
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.